CN110753701A - 治疗补体介导的疾病和障碍的方法 - Google Patents

治疗补体介导的疾病和障碍的方法 Download PDF

Info

Publication number
CN110753701A
CN110753701A CN201880029619.1A CN201880029619A CN110753701A CN 110753701 A CN110753701 A CN 110753701A CN 201880029619 A CN201880029619 A CN 201880029619A CN 110753701 A CN110753701 A CN 110753701A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880029619.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·范弗拉斯勒
G·帕里
N·E·斯塔格里亚诺
S·帕尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruikangdi Uk Ltd
Original Assignee
Bioverativ USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ USA Inc filed Critical Bioverativ USA Inc
Publication of CN110753701A publication Critical patent/CN110753701A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880029619.1A 2017-03-14 2018-03-14 治疗补体介导的疾病和障碍的方法 Pending CN110753701A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US62/471,190 2017-03-14
US201762553059P 2017-08-31 2017-08-31
US62/553,059 2017-08-31
PCT/US2018/022462 WO2018170145A1 (en) 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders

Publications (1)

Publication Number Publication Date
CN110753701A true CN110753701A (zh) 2020-02-04

Family

ID=61873979

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029619.1A Pending CN110753701A (zh) 2017-03-14 2018-03-14 治疗补体介导的疾病和障碍的方法

Country Status (14)

Country Link
US (1) US20210115116A1 (cg-RX-API-DMAC7.html)
EP (1) EP3596121A1 (cg-RX-API-DMAC7.html)
JP (3) JP7293122B2 (cg-RX-API-DMAC7.html)
KR (2) KR102934707B1 (cg-RX-API-DMAC7.html)
CN (1) CN110753701A (cg-RX-API-DMAC7.html)
AU (2) AU2018236267B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018950A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055781A1 (cg-RX-API-DMAC7.html)
CR (1) CR20190468A (cg-RX-API-DMAC7.html)
IL (2) IL269174B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019010994A (cg-RX-API-DMAC7.html)
SG (1) SG11201907583TA (cg-RX-API-DMAC7.html)
TW (2) TWI848905B (cg-RX-API-DMAC7.html)
WO (1) WO2018170145A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
CN116096354A (zh) * 2020-06-15 2023-05-09 法龙药品公司 稳定的抗clever-1抗体调配物
CN116724236A (zh) * 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
US12686713B2 (en) 2022-06-24 2026-07-21 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
PL3893924T3 (pl) 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
JP2023503611A (ja) * 2019-11-26 2023-01-31 オメロス コーポレーション 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
CN104884088A (zh) * 2012-11-02 2015-09-02 真北医疗股份有限公司 抗补体C1s抗体和其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884088A (zh) * 2012-11-02 2015-09-02 真北医疗股份有限公司 抗补体C1s抗体和其用途
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERND JILMA, MD等: "Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe,Transfusion-Dependent Cold Agglutinin Disease (CAD)", 《BLOOD》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096354A (zh) * 2020-06-15 2023-05-09 法龙药品公司 稳定的抗clever-1抗体调配物
US12662533B2 (en) 2020-06-15 2026-06-23 Faron Pharmaceuticals Oy Stable anti-clever-1 antibody formulation
CN116724236A (zh) * 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
WO2023221325A1 (zh) * 2022-05-19 2023-11-23 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
GB2622924A (en) * 2022-05-19 2024-04-03 Univ Jiangsu Complement activated CIS enzyme fluorescence detection kit, detection method, and use
US12686713B2 (en) 2022-06-24 2026-07-21 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Also Published As

Publication number Publication date
AU2025204392A1 (en) 2025-07-03
TW202513092A (zh) 2025-04-01
TWI848905B (zh) 2024-07-21
AU2018236267B2 (en) 2025-03-13
BR112019018950A2 (pt) 2020-04-22
JP2020511469A (ja) 2020-04-16
SG11201907583TA (en) 2019-09-27
TW201842931A (zh) 2018-12-16
US20210115116A1 (en) 2021-04-22
IL269174B1 (en) 2026-01-01
EP3596121A1 (en) 2020-01-22
IL269174A (en) 2019-11-28
WO2018170145A1 (en) 2018-09-20
MX2025010483A (es) 2025-10-01
JP2025072437A (ja) 2025-05-09
KR20260039796A (ko) 2026-03-20
KR102934707B1 (ko) 2026-03-06
JP7293122B2 (ja) 2023-06-19
KR20190128676A (ko) 2019-11-18
IL269174B2 (en) 2026-05-01
JP2023071824A (ja) 2023-05-23
CR20190468A (es) 2019-12-17
IL325084A (en) 2026-02-01
AU2018236267A1 (en) 2019-09-26
MX2019010994A (es) 2020-12-01
CA3055781A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
KR102934707B1 (ko) 보체-매개된 질환 및 장애의 치료 방법
US20250188192A1 (en) Anti-complement c1s antibodies and uses thereof
AU2022215307B2 (en) Methods of treating autoimmune and alloimmune disorders
CN104870475B (zh) 抗补体C1s抗体和其用途
US20250145696A1 (en) Methods for treating complement-mediated diseases and disorders
EP4444758A2 (en) Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
HK40022920A (en) Methods for treating complement-mediated diseases and disorders
US20250179213A1 (en) Pharmaceutical composition comprising anti-fxi/fxia antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40022920

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250418

Address after: Hemel Hempstead

Applicant after: Ruikangdi UK Ltd.

Country or region after: Britain

Address before: California, USA

Applicant before: BIOVERATIV USA Inc.

Country or region before: U.S.A.